Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galantamine in Mild Cognitive Impairment
NCT00236574Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- May 2001
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
01
Overview
A Phase 3 trial of galantamine in Mild Cognitive Impairment (MCI), sponsored by Johnson & Johnson. Started May 2001; status: completed.
02
Drugs
galantamine
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT00236574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00236574.